You can add Japan’s Daiichi Sankyo to the list of pharma companies restructuring their R&D organizations.
Like Takeda before it and a whole lineup of US and European pharmas, Daiichi Sankyo is shuttering a research facility in India and axing 170 staffers. And the company says it is in the process of slashing costs around the world as it frees up cash.
In a statement, the company noted:
Daiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline.
Over the years, Daiichi Sankyo — with R&D primarily located in Japan — has gathered together a far-flung operation, with US facilities in New Jersey as well as Berkeley, CA, where they bought out Plexxikon. After India closes it will also have operations in Korea, China and Taiwan. There is also a group operating in Munich.
The question now is how the company will consolidate those efforts in an era when most major operators are migrating steadily into global hubs like Boston/Cambridge/ the Bay Area, London and Shanghai.
Daiichi Sankyo just struck a classic Japanese licensing deal with Kite, paying $50 million up front to partner on their soon-to-be-filed CAR-T.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription